TNF and inflammatory bowel disease: The prescription of any immunomodulator in the first 5 years from diagnosis was stable in the years 2006–2018 (rs = 0.056; p = 0.257), but there was a slight increase in the prescription of TNF inhibitors (rs = 0.119, p = 0.020) in patients with IBD.